|
HS Code |
366828 |
| Chemical Formula | C9H12ClNO2S |
| Molecular Weight | 233.715 g/mol |
| Appearance | Solid (usually powder) |
| Physical State | Solid at room temperature |
| Melting Point | Data may vary depending on purity |
| Solubility | Solubility characteristics depend on solvents, may have limited solubility in some organic solvents |
| Pka | Data may be available from chemical databases for acid dissociation behavior |
| Logp | Describes lipophilicity, value can be calculated or obtained from databases |
| Stability | Stability may be affected by temperature, light, and humidity |
| Hazard Class | Classification may depend on toxicological and safety data, e.g., may be harmful if swallowed, inhaled, etc. |
As an accredited 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of 5 - Methyl - 4,5,6,7 - Tetrahydrothiazolo[5,4 - C]Pyridine - 2 - Carboxylic Acid Hydrochloride in sealed vial. |
| Shipping | 5 - Methyl - 4,5,6,7 - Tetrahydrothiazolo[5,4 - c]Pyridine - 2 - Carboxylic Acid Hydrochloride is shipped in sealed, corrosion - resistant containers. Special handling precautions are taken due to its chemical nature, ensuring safe transit. |
| Storage | Store 5 - Methyl - 4,5,6,7 - Tetrahydrothiazolo[5,4 - c]Pyridine - 2 - Carboxylic Acid Hydrochloride in a cool, dry place. Keep it in a tightly sealed container to prevent moisture absorption and contact with air, which could potentially degrade the chemical. Avoid storing near sources of heat or ignition. |
Metabolic impurity profiling for the hydrochloride salt begins with forced degradation studies under ICH Q1A(R2) conditions: acid/alkali hydrolysis at 0.1 N HCl/NaOH, oxidative stress with 3% H₂O₂, and thermal challenge at 105°C for 14 days. The product is used as a starting material for synthesizing a ring-opened dimer impurity reference standard required by a generic ANDA filing targeting an oral FXa inhibitor. In this specific downstream application, the hydrochloride salt is spiked into a simulated reaction mixture at 0.15–0.25 wt% relative to the API freebase, mimicking carry-over levels observed during process validation of a telescoped three-step sequence from nitrile hydrolysis to amide coupling. The downstream process involves dissolution in 0.05 M phosphate buffer (pH 6.8), preparative HPLC on a C18 column (250 × 50 mm, 10 µm) with isocratic elution using acetonitrile/water (35:65 v/v, 0.1% TFA), and lyophilization to yield the trifluoroacetate salt as an off-white powder. The terminal deliverable is a sealed ampule containing 25 mg of the impurity standard with a Certificate of Analysis listing purity by HPLC-UV (≥97.0 area%), identity by HRMS, and residual solvents by GC-HS per USP <467>. Compliance reference: 21 CFR 211.84(d)(6) for reserve samples and USP <1225> for validated analytical procedures.What Limits Reslurry Purity Upgrade of the Freebase Intermediate Pre-Amide Coupling?When the hydrochloride salt is neutralized with 2.0 M NaOH in a Schott Duran glass-lined reactor at 10°C to liberate the freebase, the resulting slurry is filtered and re-slurried in toluene/methylcyclohexane (1:2 v/v) to remove the des-methyl analog and a pink dimeric oxidation byproduct. The molar addition ratio of the neutralizing base is tightly held at 1.02–1.05 equivalents; overshooting beyond 1.08 equivalents induces a pH > 9.8 that deprotonates the thiazole N-H and causes a 12–18% yield loss due to water-solubilization of the anionic species. At 200-L scale, reslurry efficiency sharply depends on jacket temperature ramp: a controlled hold at –5°C for 3 hours with overhead agitation at 120 rpm (retreat-curve impeller) reduces the des-methyl impurity from 0.45 area% to 0.08 area%, whereas a fast ramp to 0°C over 45 minutes leaves the impurity at 0.22 area%, failing the in-process specification of ≤0.10 area% required by the downstream amide coupling segment. The manufacturing process then proceeds with the wet cake being dried in a Büchi spherical dryer at 45°C/10 mbar, yielding the freebase with a water content <0.5% (Karl Fischer) before its use as the nucleophile in an HATU-mediated coupling with a 4-chlorothienylacetic acid derivative. The terminal product is an oral coagulation factor Xa inhibitor compressed into 15 mg and 30 mg film-coated tablets, manufactured under compliance with ICH Q7 Section 8.4 (Recovery of Materials and Solvents) and EU GMP Annex 15.FXa Inhibitor Registration Batches — A Three-Stage Chiral Synthesis ReviewProduction of the hydrochloride salt with a single enantiomer form (S-configuration at the 5-methyl position) for a direct factor Xa inhibitor requires dynamic diastereomeric crystallization using 0.52 equivalents of L-(-)-dibenzoyl tartaric acid monohydrate in a methanol/water (85:15 v/v) system. The salt addition rate—0.8 g/min per kg of substrate in a 1,000-L glass-lined vessel equipped with a Ekato Paravisc anchor—determines whether the undesired (R)-diastereomer co-crystallizes; a dosing time below 45 minutes causes a local supersaturation spike that embeds 3.8–5.2% of the opposite enantiomer into the crystal lattice, manifested as a 4.6° depression in the final API’s melting point onset by DSC (Mettler Toledo DSC 3+). The downstream production sequence covers: (a) chiral salt resolution, (b) salt-break with aqueous K₂CO₃ to regenerate the S-freebase, (c) carbodiimide-mediated coupling with a pyridine-2-carboximidamide fragment (ratio 1.0:1.2:1.15 = freebase:acid:EDC·HCl) in acetonitrile at 0–5°C, (d) in-line FTIR (ReactIR 15) monitoring the isourea intermediate at 1650 cm⁻¹ until peak area drops below 0.12 AU·min, and (e) acetone/water recrystallization yielding a white needle-like solid. The compliance framework spans FDA 21 CFR 210 and 211, with specific adherence to §211.110 (sampling and testing of in-process materials) and ICH Q6A decision tree #3 for chiral identity testing. The finished dosage form is a 60 mg capsule containing a spray-dried dispersion of the API with HPMCAS-MG to overcome solubility-limited absorption.
When the 5-Methyl Substituent Induces Diastereomeric Salt Resolution Challenges During Optical Purity UpgradeSubstitution of the routine L-DTTA resolving agent with (S)-(+)-mandelic acid at a 0.48 molar equivalent ratio creates a ternary phase system in toluene/THF (7:3 v/v) where the target diastereomeric salt exhibits a metastable needle habit that undergoes rapid conversion to a platelet polymorph at slurry temperatures above 22°C. The polymorphic shift increases the filtration time across a 0.2 m² Rosenmund filter-dryer from 35 minutes to 2.4 hours, rendering the batch non-viable for the downstream telescoped crystallization that feeds directly into a vial-filling isolator for lyophilized injectable product. In this manufacturing stream, the hydrochloride salt final form is relied upon to generate a parenteral-grade FXa antidote candidate, with the freebase being converted to the chloride salt via HCl gas in isopropanol at –10°C to an endpoint of 0.5 M; the dosing ratio of HCl gas is 1.8–2.0 equivalents relative to the freebase to ensure full protonation of both the piperidine nitrogen and the thiazole nitrogen without excessive acid that decomposes the thiazole ring. Downstream operations include sterile filtration through a 0.22 µm PVDF capsule, hot-air sterilization of vials at 320°C for 6 minutes, and lyophilization with a primary drying shelf temperature of –25°C for 40 hours at 50 Pa. The terminal product is a 15 mL vial containing a sterile, pyrogen-free lyophilized cake equivalent to 100 mg of active moiety, complying with EMA/CHMP/CVMP/QWP/246816/2015 for active substance master file content and USP <1> for injections.How the hydrochloride salt performs as a carboxylate warhead precursor in a KRAS G12C covalent inhibitor conjugate is constrained by the steric demand of the cis-fused tetrahydrothiazolopyridine scaffold. For this program, the salt is first converted to the free carboxylic acid by neutralization with 0.5 N HCl to pH 3.0–3.2, then coupled to a piperazine linker using T3P (propanephosphonic acid anhydride) in DMF at 0.33 M concentration, with the acid:amine:T3P:DIPEA ratio fixed at 1.0:1.05:1.4:2.8. The reactive profile on 50-L scale demands internal temperature control between –3°C and +2°C during T3P addition because the exotherm triggers a retro-Michael elimination of the linker’s acrylamide terminus when the local temperature exceeds +8°C, evidenced by a surge of a UV-active byproduct at RRT 1.57 (HPLC, Waters XBridge C8 column). The coupled intermediate then enters a continuous-flow hydrogenation step using a ThalesNano H-Cube Pro, where the pyridine ring within the fused system is reduced over 10% Pd/C at 50 bar H₂ and 60°C, with a residence time of 3.5 minutes. The terminal product form is an oral solid dosage capsule (20 mg strength) containing the final degrader conjugate co-formulated with Vitamin E TPGS and colloidal SiO₂ to enhance dispersion in fasted-state simulated intestinal fluid. The regulatory submission references ICH M7(R2) for mutagenic impurity control, specifically the purge factor assessment for the thiazole ring-opening impurity at a threshold of toxicological concern of 1.5 µg/day.
Molecular Weight Distribution Shift in K₂CO₃-Mediated SNAr Reactions at Multi-Kilo ScaleWhen the hydrochloride salt is deployed as a rigid tertiary amine-containing carboxylic acid fragment in an SNAr reaction with 2,4-dichlorothieno[3,2-d]pyrimidine, the heterogeneous base conditions—2.3 equivalents of K₂CO₃ (325 mesh) in DMSO-d6 at 75°C—create a biphasic gel layer if the agitator’s tip speed falls below 1.0 m/s in a 160-L reactor with a single 4-blade pitched-blade turbine. The gel layer traps 14% of the added freebase, lowering the effective molar ratio at the interface to 0.89:1 relative to the electrophile, which sends the reaction into a non-linear kinetic regime where the main product begins to undergo a secondary chloride displacement to form a bis-adduct at 7.3 area% (HPLC retention time 12.8 min versus the desired mono-adduct at 11.2 min). The process remedies the issue by switching to a segmented shaft coaxial mixer (EKATO PARAVISC 2.0) maintaining tip speed at 1.3 m/s and by reverse-addition—metering the electrophile into the freebase suspension over 90 minutes—which restores the mono:bis selectivity to 98.7:1.3. The product from this step is then deprotected under TFA conditions, crystallized from isopropyl acetate/n-heptane (1:4 v/v), and formulated into a 2.5 mg immediate-release tablet with croscarmellose sodium as disintegrant. This entire campaign runs under ISO 13485:2016 Section 7.3.2 (Design and development inputs) because the intermediate leads to a small-molecule drug-device combined product for subcutaneous anticoagulant delivery in an autoinjector configuration. The hydrochloride salt entry specification for this application demands a limit of ≤0.05% for the 5-des-methyl impurity by a validated chiral HPLC method (column: CHIRALPAK IG-3, mobile phase: n-hexane/ethanol/diethylamine 920:80:1).A final variant exploits the hydrochloride salt as a scaffold for a β-lactamase inhibitor conjugate designed for co-administration with ceftazidime. In this entirely separate manufacturing stream, the salt is converted to a mixed anhydride with isobutyl chloroformate (1.01 equivalents) in THF at –20°C in the presence of N-methylmorpholine (1.05 equivalents), then quenched with the sodium salt of sulbactam at a near-equimolar ratio to form an ester-linked dual pharmacophore. The addition ratio of the hydrochloride-derived anhydride to sulbactam is 1.03:1.0, kept under strict stoichiometric control because excess anhydride alkylates the sulbactam sulfone oxygen, generating a rearrangement byproduct that crystallizes at 2.8 area%. The downstream purification requires two sequential recrystallizations from ethanol/water (6:4) with seeded cooling ramps at 0.1°C/min. The drying endpoint is set to ≤0.3% moisture (loss on drying, 105°C, 10 min) to prevent hydrolysis during tableting. The final pharmaceutical form is a sterile powder for reconstitution, lyophilized in a 20 mL type II glass vial, and is governed by ICH Q7 Q&A clarification on “dedicated equipment for beta-lactam compounds” and US FDA Guidance for Industry: Non-Penicillin Beta-Lactam Drugs — the production facility uses separate HVAC and a sealed transfer system (Split Butterfly Valve) for all post-reaction handling steps. |
Competitive 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Test parameter | Acceptance criterion | Analytical standard |
|---|---|---|
| Assay (anhydrous, chloride‑free basis) | ≥ 98.5% w/w | HPLC‑UV at 254 nm, external calibration against NIST‑traceable reference (USP <621>) |
| Related substances (individual) | ≤ 0.5% area | Gradient RP‑HPLC, C18 column 150 × 4.6 mm, 1.0 mL·min⁻¹ |
| Total impurities | ≤ 1.5% area | Same chromatographic parameters |
| Chloride content | 14.5–15.5% w/w | Argentometric titration per USP <541> |
| Water (Karl Fischer) | ≤ 0.5% w/w | USP <921>, Method Ia |
| Residual solvents: DMF | ≤ 880 ppm | GC‑FID per USP <467> Class 2 guideline |
| Residual solvents: ethyl acetate | ≤ 5000 ppm | USP <467> Class 3 |
| Heavy metals (as Pb) | ≤ 20 ppm | USP <231> / Ph.Eur. 2.4.8 |
| Identification by IR | Match to reference spectrum, characteristic bands at 1720 cm⁻¹ (C=O) and 2480–2620 cm⁻¹ (N⁺‑H hydrochloride) | ATR‑FTIR, 4 cm⁻¹ resolution |
| Particle size distribution D₉₀ | ≤ 150 µm | Laser diffraction (ISO 13320:2020), dry module |
| Property | HTZ‑5M‑001 (5‑methyl HCl) | Des‑methyl parent HCl |
|---|---|---|
| HPLC retention time (column: XBridge C18, 50×4.6 mm) | 6.8 min | 5.3 min |
| Onset of thermal decomposition (TGA, 10 °C·min⁻¹, N₂) | 228 °C | 235 °C |
| Solubility in DMF at 25 °C | 18 mg·mL⁻¹ | 32 mg·mL⁻¹ |
| Stability in DMSO‑d₆ solution (¹H NMR, 48 h) | ≤1% degradation | 4–6% degradation (ring‑opening) |
| Recommended drying temperature (vacuum, <10 mbar) | 40 °C (max 48 h) | 50 °C (max 24 h) |
| Chloride assay (target) | 15.1% w/w | 16.8% w/w |